Evidence map›Paper›PMID 29288430›Full record

ArticleTransgenic research2018

Co-precipitation molecules hemopexin and transferrin may be key molecules for fibrillogenesis in TTR V30M amyloidogenesis.

Mika Ohta, Aki Sugano, Naoya Hatano, Hirotaka Sato, Hirofumi Shimada, Hitoshi Niwa, Toshiyuki Sakaeda, Hajime Tei, Yoshiyuki Sakaki, Ken-Ichi Yamamura and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Transgenic research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Genotype-Phenotype Correlation inKidney international reports · 2021
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 1 country.

Mika OhtaDivision of Medical Informatics and Bioinformatics, Kobe University Hospital, Kobe, 650-0017, Japan.
Aki SuganoDivision of Medical Informatics and Bioinformatics, Kobe University Hospital, Kobe, 650-0017, Japan.
Naoya HatanoThe Integrated Center for Mass Spectrometry, Kobe University Graduate School of Medicine, Kobe, 650-0017, Japan.
Hirotaka SatoDepartment of Pathology, Division of Anatomical and Cellular Pathology, Iwate Medical University, Morioka, 028-3694, Japan.
Hirofumi ShimadaInstitute of Molecular Embryology and Genetics, Kumamoto University, Kumamoto, 860-0811, Japan.
Hitoshi NiwaInstitute of Molecular Embryology and Genetics, Kumamoto University, Kumamoto, 860-0811, Japan.
Toshiyuki SakaedaDepartment of Phamacokinetics, Kyoto Pharmaceutical University, Kyoto, 607-8414, Japan.
Hajime TeiHuman Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan.
Yoshiyuki SakakiHuman Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan.
Ken-Ichi YamamuraInstitute of Molecular Embryology and Genetics, Kumamoto University, Kumamoto, 860-0811, Japan.
Yutaka TakaokaDivision of Medical Informatics and Bioinformatics, Kobe University Hospital, Kobe, 650-0017, Japan. ytakaoka@ebraille.med.kobe-u.ac.jp.ORCID 0000-0001-7568-8135
Kobe University Hospital · JPKumamoto University · JPThe University of Tokyo · JPIwate Medical University · JPKobe University · JPKumamoto Industrial Research Institute · JPKyoto Pharmaceutical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The disease model of familial amyloidotic polyneuropathy-7.2-hMet30 mice-manifests amyloid deposition that consists of a human amyloidogenic mutant transthyretin (TTR) (TTR V30M). Our previous study found amyloid deposits in 14 of 27 7.2-hMet30 mice at 21-24 months of age. In addition, non-fibrillar TTR deposits were found in amyloid-negative 7.2hMet30 mice. These results suggested that TTR amyloidogenesis required not only mutant TTR but also an additional factor (or factors) as an etiologic molecule. To determine the differences in serum proteome in amyloid-positive and amyloid-negative mice in the 7.2-hMet30 model, we used proteomic analyses and studied serum samples obtained from these mice. Hemopexin (HPX) and transferrin (Tf) were detected in the serum samples from amyloid-positive mice and were also found in amyloid deposits via immunohistochemistry, but serum samples from amyloid-negative mice did not contain HPX and Tf. These two proteins were also not detected in non-fibrillar TTR deposits. In addition, in silico analyses suggested that HPX and Tf facilitate destabilization of TTR secondary structures and misfolding of TTR. These results suggest that HPX and Tf may be associated with TTR amyloidogenesis after fibrillogenesis in vivo.

Indexed as

AmyloidAmyloid Neuropathies, FamilialAnimalsBlood ProteinsComputer SimulationDisease Models, AnimalElectrophoresis, Polyacrylamide GelHemopexinHumansIntestine, SmallMice, TransgenicMolecular Dynamics SimulationPrealbuminTransferrinAmyloidamyloid prealbuminBlood ProteinsHemopexinPrealbuminTransferrinHemopexinMolecular dynamics simulationProteomic analysisTransferrinTTR amyloidogenesis

Identifiers

PMID29288430
PMCPMC5847157
OpenAlexW2780372885

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.